ES2037499T3 - Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix. - Google Patents

Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix.

Info

Publication number
ES2037499T3
ES2037499T3 ES199090107974T ES90107974T ES2037499T3 ES 2037499 T3 ES2037499 T3 ES 2037499T3 ES 199090107974 T ES199090107974 T ES 199090107974T ES 90107974 T ES90107974 T ES 90107974T ES 2037499 T3 ES2037499 T3 ES 2037499T3
Authority
ES
Spain
Prior art keywords
adsorption
procedure
blood coagulation
isolation
elution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES199090107974T
Other languages
English (en)
Inventor
Wolfgang Dr. Dipl.-Chem. Moller
Michael Dipl.-Biol. Kraus
Bertram Dr. Eichentopf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest Pharma GmbH
Original Assignee
Biotest Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest Pharma GmbH filed Critical Biotest Pharma GmbH
Application granted granted Critical
Publication of ES2037499T3 publication Critical patent/ES2037499T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

EL INVENTO SE REFIERE A UN PROCEDIMIENTO PARA AISLAR FACTORES (IX) DE COAGULACION SANGUINEA, QUE CONSISTE EN ADSORCION DE PLASMA O DE UNA SOLUCION O FRACCION DE PLASMA QUE CONTIENE EL FACTOR (IX) POR UN ADSORBENTE QUE LLEVA EL GRUPO (ALFA)-HIDROXILO-AMINO, ELUCION DE LA ADSORVION CON UNA AMINA ORGANICA PRIMARIA Y DE BAJO PESO MOLECULAR; ADSORCION DEL ELNATO EN UNA MATRIZ QUE LLEVA HIDRATOS DE CARBONO SULFATADOS, ELUCION DE LA ADSORCION CON UN GRADIENTE DE SAL, CONCENTRACION DE LA ELUCION Y ENFRIAMIENTO A BAJO CERO DE LA CONCENTRACION Y SE CARACTERIZA PROQUE ANTES O DESPUES DE LA PRIMERA ADSORCION SE EFECTUA LA INACTIVACION DE LOS VIRUS PRESENTES A TRAVES DE MEDIDAS CONOCIDAS.
ES199090107974T 1989-05-05 1990-04-26 Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix. Expired - Lifetime ES2037499T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3914869A DE3914869C1 (es) 1989-05-05 1989-05-05

Publications (1)

Publication Number Publication Date
ES2037499T3 true ES2037499T3 (es) 1993-06-16

Family

ID=6380171

Family Applications (1)

Application Number Title Priority Date Filing Date
ES199090107974T Expired - Lifetime ES2037499T3 (es) 1989-05-05 1990-04-26 Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix.

Country Status (8)

Country Link
US (1) US5061789A (es)
EP (1) EP0396022B1 (es)
JP (1) JP2593951B2 (es)
AT (1) ATE76751T1 (es)
DE (2) DE3914869C1 (es)
DK (1) DK0396022T3 (es)
ES (1) ES2037499T3 (es)
GR (1) GR3005036T3 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402261B (de) * 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
AT395597B (de) * 1991-01-25 1993-01-25 Immuno Ag Reagens zur bestimmung von faktor viii-aktivitaet
DK0573605T3 (da) * 1991-03-01 2001-01-02 Rhone Poulenc Rorer Int Fremstilling af faktor IX
IT1262899B (it) * 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
DE19504852C2 (de) * 1995-02-15 2003-01-23 Octapharma Ag Lachen Verfahren zur Reinigung Vitamin K-abhängiger Gerinnungsfaktoren durch Affinitäts-Chromatographie
US5714583A (en) * 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
DE10045434B4 (de) * 2000-09-14 2005-07-14 Fresenius Hemocare Gmbh Adsorbens mit unterschiedlich modifizierten Oberflächenbereichen, Verfahren zu dessen Herstellung und Verwendung davon
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
EP3938742A1 (en) 2019-03-14 2022-01-19 Terumo BCT Biotechnologies, LLC Multi-part lyophilization container and method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920625A (en) * 1973-06-19 1975-11-18 Kabi Ab Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
EP0041174B1 (en) * 1980-05-27 1985-09-11 Miles Laboratories, Inc. Blood coagulation promoting product and process of preparing same
DE3033932C2 (de) * 1980-09-10 1984-05-24 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten
DE3101752A1 (de) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
DE3826792C1 (es) * 1988-08-06 1989-07-06 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
GR3005036T3 (es) 1993-05-24
JPH02306994A (ja) 1990-12-20
JP2593951B2 (ja) 1997-03-26
EP0396022A1 (de) 1990-11-07
ATE76751T1 (de) 1992-06-15
US5061789A (en) 1991-10-29
EP0396022B1 (de) 1992-06-03
DE59000141D1 (de) 1992-07-09
DK0396022T3 (da) 1992-07-20
DE3914869C1 (es) 1990-08-09

Similar Documents

Publication Publication Date Title
ES2037499T3 (es) Procedimiento para el aislamiento del factor de la coagulacion sanguinea ix.
Morisawa et al. Cyclic AMP induces maturation of trout sperm axoneme to initiate motility
Mutti et al. Brain dopamine as a target for solvent toxicity: effects of some monocyclic aromatic hydrocarbons
YU227790A (sh) Uporaba težko topne soli heteropolikisline za določanje analita, ustrezni postopek za določanje kot tudi za to primerno sredstvo
ES2028865T3 (es) Procedimiento mejorado para la preparacion de derivados de macrolidas.
ES532880A0 (es) Un procedimiento para obtener composiciones farmaceuticas que contienen un derivado del acido 3-hidroxibutanoico y de una base inorganica u organica nitrogenada.
CO4650143A1 (es) Kit para deteccion de helicobacter pylori
ES2068975T3 (es) Metodo de separacion y agente de separacion.
Jantzie et al. Doxycycline inhibits proinflammatory cytokines but not acute cerebral cytogenesis after hypoxia–ischemia in neonatal rats
ES2531084T3 (es) Proceso para la preparación de 2-cianopirrolidinas n-sustituidas
ES521086A0 (es) Procedimiento para la preparacion de imidazolilfenil-tetrahidropiridazinas.
Craighead et al. Encephalomyocarditis virus hemagglutination-inhibition test using antigens prepared in HeLa cell cultures
CO2021016295A2 (es) Compuestos de pirrolidina
Schuldiner et al. On the mechanism of the energy-dependent quenching of atebrin fluorescence in isolated chloroplasts
Anderson The activity of a bacteriostatic substance in the reaction between bacterial virus and host
AR012124A1 (es) Un procedimiento para la preparacion de derivados de tiazolidinadiona, derivados de tiazolidinadiona, su uso y preparados farmaceuticos que contienen a dichos derivados.
Korotkov Effects of Tl+ on ion permeability, membrane potential and respiration of isolated rat liver mitochondria
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk
ES2072492T3 (es) Derivados de acido piridinalqueno- y -aminooxialcano-carboxilico sustituidos por fenilsulfonamida.
KATZ et al. Effects of local anaesthetics on calcium transport by canine cardiac microsomes (fragmented sarcoplasmic reticulum)
BR112022010537A2 (pt) Terapia para o tratamento do câncer
Kato et al. Fluorometric determination of nicotinamide by use of synthetic ion exchange resins
ES2032535T3 (es) Ensayos para la determinacion de componentes biologicamente acticos de fluidos biologicos.
Nishmi et al. The microepidemiology of vaccinial infection as studied in HeLa cell stationary cultures
ES2146049T3 (es) Benzoilguanidinas, procedimiento para su preparacion y medicamento que las contiene.